Physician profile
Khawar Gul
NPI 1538296744
$10,117.27
in general payments reported to CMS, 2019-2025
26 companies · $1,951 in 2025
The $1,951 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,519 · 2020: $724 · 2021: $1,313 · 2022: $1,614 · 2023: $1,478 · 2024: $1,519 · 2025: $1,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,948.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,577.32 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,502.26 | 2019-2025 | Farxiga, Lokelma, Andexxa |
| Janssen Pharmaceuticals, INC | $1,096.90 | 2019-2024 | Xarelto |
| Pfizer INC. | $785.58 | 2019-2025 | |
| Medtronic, INC. | $575.33 | 2021-2024 | Selectsecure, Linq II |
| E.R. Squibb & Sons, L.L.C. | $556.69 | 2019-2024 | Eliquis, Camzyos |
| Scpharmaceuticals INC. | $540.89 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $526.04 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $517.28 | 2019-2025 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.86 | 2020-2025 | Jardiance |
| Edwards Lifesciences Corporation | $301.57 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic Vascular, INC. | $229.40 | 2020 | |
| Esperion Therapeutics, INC. | $195.82 | 2024-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $155.53 | 2023-2024 | Inpefa |
| Abbott Laboratories | $144.52 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $144.25 | 2019 | |
| Amarin Pharma, INC. | $140.77 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $131.48 | 2022 | |
| Philips North America LLC | $123.71 | 2023 | |
| Abiomed | $117.36 | 2024-2025 | Impella |
| Covidien LP | $116.07 | 2019 | |
| Amgen INC. | $114.49 | 2024-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $80.19 | 2025 | |
| Irhythm Technologies, INC. | $31.04 | 2022 | |
| Canon Medical Systems USA, INC. | $19.14 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.78 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khawar Gul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.